RecruitingPhase 3NCT05421858
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
Studying Invasive candidiasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Basilea Pharmaceutica
- Principal Investigator
- Manuel Häckl, MDBasilea Pharmaceutica International Ltd, Allschwil
- Intervention
- Fosmanogepix(drug)
- Enrollment
- 450 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (30)
- University of Alabama at Birmingham School of Medicine, Department of Medicine, Birmingham, Alabama, United States
- City of Hope, Duarte, California, United States
- David Geffen School of Medicine at UCLA, Los Angeles, California, United States
- UC Davis Medical Center, Sacramento, California, United States
- Emory University Hospital - Clifton Road, Atlanta, Georgia, United States
- Augusta University Medical Center, Augusta, Georgia, United States
- Indiana University Methodist Hospital, Indianapolis, Indiana, United States
- University of Kentucky College of Medicine, Lexington, Kentucky, United States
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- University of Michigan Health System (UMHS) - A. Alfred Taubman Health Care Center, Ann Arbor, Michigan, United States
- DMC Harper University Hospital, Detroit, Michigan, United States
- Henry Ford Hospital, Department of Medicine, Division of Infectious Diseases, Detroit, Michigan, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Washington University School of Medicine, Infectious Diseases Clinical Research Unit, St Louis, Missouri, United States
- Weill Cornell Medical College - NewYork-Presbyterian Hospital, New York, New York, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Biomedical Advanced Research and Development Authority
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05421858 on ClinicalTrials.govOther trials for Invasive candidiasis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06194201A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive CandidiasisFujian Shengdi Pharmaceutical Co., Ltd.
- RECRUITINGNCT06456151Invasive Candidiasis in Critical CareUniversity Hospital Ostrava
- RECRUITINGNANCT05763251Comparison of Uncomplicated Candidemia Therapy Duration in ChildrenArkansas Children's Hospital Research Institute
- ACTIVE NOT RECRUITINGPHASE3NCT04368559Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow TransplantationMundipharma Research Limited
- RECRUITINGNANCT03538912Early Discontinuation of Empirical Antifungal Therapy and BiomarkersUniversity Hospital, Lille